Abstract:Antibody–drug conjugates (ADCs) are an innovative family of agents assembled through linking cytotoxic drugs (payloads) covalently to monoclonal antibodies (mAbs) to be delivered to tumor tissue that express their particular antigen, with the theoretical advantage of an augmented therapeutic ratio. As of June 2023, eleven ADCs have been approved by the Food and Drug Administration (FDA) and are on the market. These drugs have been added to the therapeutic armamentarium of acute myeloblastic and lymphoblastic leukemias, various types of lymphoma, breast, gastric or gastroesophageal junction, lung, urothelial, cervical, and ovarian cancers. They have proven to deliver more potent and effective anti-tumor activities than standard practice in a wide variety of indications. In addition to targeting antigen-expressing tumor cells, bystander effects have been engineered to extend cytotoxic killing to low-antigen-expressing or negative tumor cells in the heterogenous tumor milieu. Inevitably, myelosuppression is a common side effect with most of the ADCs due to the effects of the cytotoxic payload. Also, other unique side effects are specific to the tissue antigen that is targeted for, such as the cardiac toxicity with Her-2 targeting ADCs, and the hemorrhagic side effects with the tissue factor (TF) targeting Tisotumab vedotin. Further exciting developments are centered in the strategies to improve the tolerability and efficacy of the ADCs to improve the therapeutic window; as well as the development of novel payloads including (1) peptide–drug conjugates (PDCs), with the peptide replacing the monoclonal antibody, rendering greater tumor penetration; (2) immune-stimulating antibody conjugates (ISACs), which upon conjugation of the antigen, cause an influx of pro-inflammatory cytokines to activate dendritic cells and harness an anti-tumor T-cell response; and (3) the use of radioactive isotopes as a payload to enhance cytotoxic activity.

Antibody drug conjugates: Design implications for clinicians

A comprehensive review of key factors affecting the efficacy of antibody drug conjugate

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Antibody drug conjugates in the clinic

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy

Targeting cancer with antibody-drug conjugates: Promises and challenges

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

Unlocking the potential of antibody–drug conjugates for cancer therapy

Advances and Limitations of Antibody Drug Conjugates for Cancer

Antibody–drug conjugates come of age in oncology

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement

The Evolving Therapeutic Landscape of Antibody-Drug Conjugates in Breast Cancer.

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Exploring the next generation of antibody–drug conjugates

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities